A clinician's paradigm in the treatment of psoriasis

被引:78
作者
Lebwohl, M [1 ]
机构
[1] CUNY Mt Sinai Sch Med, Dept Dermatol, New York, NY 10029 USA
关键词
D O I
10.1016/j.jaad.2005.04.031
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 [皮肤病与性病学];
摘要
Psoriasis is a chronically recurring inflammatory disease that affects the skin, scalp, and joints. It ranges in severity from mild to severe, and patients with moderate to severe disease experience significant deterioration in quality of life. The goals of psoriasis treatment are to gain initial and rapid control of the disease process, decrease the percentage of body surface area involved, decrease plaque lesions, achieve and maintain long-term remission, minimize adverse events, and improve patient quality of life. Therapy varies depending on disease severity and spread and will shift from control of acute flares to long-term maintenance. Topical treatment for mild psoriasis includes the use of topical corticosteroids, calcipotriene, tazarotene, topical tars, anthralin, and keratolytics. Treatment of moderate to severe psoriasis includes systemic therapies, such as methotrexate, acitretin, cyclosporine, and biologic agents. Treatment can be effected using combination, rotational, or sequential regimens. Treatment algorithms developed by a 2002 consensus conference are described. Because some degree of therapy will always be necessary, ranging from maintenance of long-term remission to control of acute psoriasis flares, each patient requires an individualized plan.
引用
收藏
页码:S59 / S69
页数:11
相关论文
共 64 条
[1]
Psoriasis remission time at the Dead Sea [J].
Abels, DJ ;
Harari, M .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2000, 43 (02) :325-326
[2]
Clearance is not a realistic expectation of psoriasis treatment [J].
Al-Suwaidan, SN ;
Feldman, SR .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2000, 42 (05) :796-802
[3]
Alli N, 1998, BRIT J DERMATOL, V139, P754
[4]
A MULTICENTER, PARALLEL-GROUP COMPARISON OF CALCIPOTRIOL OINTMENT AND SHORT-CONTACT DITHRANOL THERAPY IN CHRONIC PLAQUE PSORIASIS [J].
BERTHJONES, J ;
CHU, AC ;
DODD, WAH ;
GANPULE, M ;
GRIFFITHS, WAD ;
HAYDEY, RP ;
KLABER, MR ;
MURRAY, SJ ;
ROGERS, S ;
JURGENSEN, HJ .
BRITISH JOURNAL OF DERMATOLOGY, 1992, 127 (03) :266-271
[5]
CALLIS KP, 2003, THERAPY MODERATE SEV, P29
[6]
Rational design of receptor-selective retinoids [J].
Chandraratna, RAS .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1998, 39 (04) :S124-S128
[8]
Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UV-B [J].
Coven, TR ;
Burack, LH ;
Gilleaudeau, P ;
Keogh, M ;
Ozawa, M ;
Krueger, JG .
ARCHIVES OF DERMATOLOGY, 1997, 133 (12) :1514-1522
[9]
ELLIS CN, 2003, THERAPY MODERATE SEV, P151
[10]
FARBER EM, 1992, CUTIS, V49, P396